ICER sets fair price for tirzepatide at around $5,600 per year

Influential US pricing watchdog ICER - the Institute for Clinical and Economic Review - has released a final report into the cost-effectiveness of Eli Lilly’s (NYSE: LLY) GLP-1 agonist tirzepatide.

The treatment is a rival to Novo Nordisk’s (NOV: N) semaglutide, sold under the brand names Ozempic and Rybelsus, a major driver of growth in the diabetes field.

The ICER’s report finds that the evidence is “adequate to demonstrate a net health benefit when tirzepatide added to background therapy is compared to background therapy alone.”